New peptide therapy for retinal diseases
Official title: Open Label, Interventional Single Arm Study Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies
Run by Ace Cells Lab Limited · NCT06787482 · Data updated 2026-11-12
This study is testing a new peptide therapy to see if it can help adults with retinal diseases like age-related macular degeneration and diabetic retinopathy improve their vision and eye health.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Ace Cells Lab Limited Industry-sponsored |
| Locations | 2 sites (Cairo and 1 other locations) |
| Status | Recruiting |
| Started | November 12, 2024 |
| Main results expected | June 2025 |
| Study ends | December 2025 |
| Registry record updated | April 25, 2025 |
| Trial ID | NCT06787482 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18-65 with a confirmed diagnosis of retinal dystrophies, AMD, or DR and stable ocular conditions.
✕Probably not a fit
Patients with significant ocular comorbidities, recent ocular surgery, or uncontrolled systemic conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates a novel peptide-based therapy aimed at treating retinal dystrophies, age-related macular degeneration (AMD), and diabetic retinopathy (DR). The therapy involves sublingual administration of peptides derived from fetal tissues and mesenchymal stem cells, combined with bioactive growth factors. The study is designed as an open-label, single-arm intervention with 150 adult participants, focusing on safety, tolerability, and improvements in retinal function and structure over a 12-month period.
Why it matters
Potential benefit: If successful, this therapy could significantly improve vision and retinal health for patients suffering from these debilitating conditions.
How similar studies have gone: While peptide therapies are a novel approach in this context, similar studies have shown promise in other areas of regenerative medicine.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * • Adults aged 18-65 years with a confirmed genetic or clinical diagnosis of RP. * Visual acuity of ≥1/60 in at least one eye. * Stable ocular and systemic condition over the past six months. * Ability to provide written informed consent Exclusion Criteria: * • Significant ocular comorbidities (e.g., advanced glaucoma, diabetic retinopathy). * Recent ocular surgery (within six months) or current use of investigational drugs. * Systemic conditions affecting study outcomes (e.g., uncontrolled diabetes, autoimmune diseases). * Pregnancy or lactation.
Where it's running
-
Dr. Seif Clinic
Cairo, Egypt Recruiting -
British Center for Regeerative medicne (Cairo)
Giza, Egypt Recruiting
Study contacts
- Principal investigator: Dr. Passant Sayed Saif, PhD ophthalmology — Associate prof of Ophthalmology Misr University for science and technology
- Study coordinator: Dr. Alaa Abdelkairm Mohammed, MRCPUK Endocrinology
- Email: dralaakarim@gmail.com
- Phone: +447473922553
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Hyperspectral imaging to map retinal and optic nerve structures
This study will test whether hyperspectral retinal imaging can detect disease-related features in adults with diabetic retinopathy, glaucoma, age-related macular degeneration, and in healthy volunteers.
-
High Resolution Imaging OCT Study
This study tests whether two investigational OCT devices (R1 and HighRes OCT) produce better image quality than the standard Spectralis in adults with normal eyes or with AMD, diabetic retinopathy, or other retinal diseases.
-
Vision screening in general practice to catch preventable sight loss in people over 70
This project will test a GP-based vision-screening program for people aged 70 and older with at least one chronic condition to find sight problems early.
-
Watching a short video before anti-VEGF eye injections
This trial will test whether watching a brief procedural video before a first anti-VEGF intravitreal injection helps people with retinal diseases feel less anxious and have fewer or smaller subconjunctival hemorrhages.
-
Improving follow-up after an eye screening referral
This trial tries text message or health worker reminders to help people referred after an eye screening get to their hospital appointment within 21 days.
-
Understanding Age-Related Macular Degeneration and Its Progression
This study looks at how age-related macular degeneration develops and progresses by comparing people with the condition to healthy individuals, using non-invasive tests and personal feedback.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.